Innoviva (INVA) Total Current Liabilities (2010 - 2026)
Innoviva (INVA) posted Total Current Liabilities of $36.6 million for Q1 2026, down 26.44% on a QoQ basis from $49.7 million in Q4 2025, and down 84.43% year-over-year from $234.7 million in Q1 2025.
Innoviva (INVA) Total Current Liabilities (2010 - 2026) Analysis & Trends
Innoviva's Total Current Liabilities history runs 17 years deep, the most recent figure standing at $36.6 million for Q1 2026.
- Quarterly Total Current Liabilities fell 84.43% year-over-year to $36.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $36.6 million (down 84.43% YoY) and the FY2025 annual result came in at $49.7 million, down 78.95% from the prior year.
- Total Current Liabilities was $36.6 million for Q1 2026 at Innoviva, down from $49.7 million in the prior quarter.
- Across five years, Total Current Liabilities topped out at $246.6 million in Q2 2025 and bottomed at $7.0 million in Q3 2022.
- A 5-year average of $96.1 million and a median of $49.7 million in 2025 frame the typical range for Total Current Liabilities.
- Annual changes were most pronounced in 2022 — Total Current Liabilities jumped 2771.37% — and 2026, when it tumbled 84.43%.
- Innoviva's Total Current Liabilities stood at $135.0 million in 2022, then tumbled by 71.75% to $38.1 million in 2023, then surged by 519.09% to $236.1 million in 2024, then slumped by 78.95% to $49.7 million in 2025, then dropped by 26.44% to $36.6 million in 2026.
- Business Quant data shows INVA's Total Current Liabilities at $36.6 million in Q1 2026, $49.7 million in Q4 2025, and $140.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 56.01 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 66.94 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 1.81 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 6.38 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 3.88 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 5.11 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.58 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 289.60 Mn |
| 10 | Innoviva | 1.57 Bn | 969.11 Mn | 75.83 Mn | 36.56 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 36.56 Mn |
| Dec 31, 2025 | 49.70 Mn |
| Sep 30, 2025 | 139.95 Mn |
| Jun 30, 2025 | 246.56 Mn |
| Mar 31, 2025 | 234.75 Mn |
| Dec 31, 2024 | 236.08 Mn |
| Sep 30, 2024 | 118.20 Mn |
| Jun 30, 2024 | 28.21 Mn |
| Mar 31, 2024 | 29.88 Mn |
| Dec 31, 2023 | 38.13 Mn |
| Sep 30, 2023 | 21.88 Mn |
| Jun 30, 2023 | 39.40 Mn |
| Mar 31, 2023 | 38.14 Mn |
| Dec 31, 2022 | 134.97 Mn |
| Sep 30, 2022 | 7.00 Mn |
| Jun 30, 2022 | 125.91 Mn |
| Mar 31, 2022 | 109.23 Mn |
| Dec 31, 2021 | 5.81 Mn |
| Sep 30, 2021 | 5.25 Mn |
| Jun 30, 2021 | 5.37 Mn |